Text Size
Santen Global

2020 Information

RSS

Information

Santen to Present Latest Data on MicroShunt at 14th EGS Congress
Ciclosporin Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18, has been added to China's third batch of Overseas New Drugs Urgently Needed in Clinical Settings, compiled by the NMPA
Santen Announces U.S. FDA Filling Acceptance of New Drug Application(NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18
Santen China won the Best Ophthalmic Public Education Award at the 2020 Chinese Ophthalmologist Association (COA) Annual Conference
Integrated Report Santen Report 2020 has been published
Announcing Addition of Third Building to Shiga Product Supply Center's Site
Santen, Verily Announce Joint Venture
Corporate Social Responsibility (CSR) page on our website has been updated
Santen's Proposed New Working Styles under the New Normal
Announcement of New Long-Term Vision
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 3)
Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 2)
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 1)
Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved